SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Premature birth needs to be in specialist centres - study
Thurs October 17th - Women facing premature labour should be enabled to give birth in hospitals with specialist neonatal intensive care units, researchers say today. More
How GPs can respond to private gene test results
Thurs October 17th - Doctors confronted by patients armed with the results of private gene testing should check for family genetic history that might support the claimed results, according to experts today. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OTHER NEWS FEEDS OF INTEREST
ENGLEMED HEALTH NEWS

Study challenges paclitaxel coating fears

Wednesday October 9th, 2019

There is no evidence of increased mortality risk from the use of paclitaxel coated devices, according to an analysis published today.

Following a safety alert earlier this year, German researchers set out to study mortality risk among patients using devices coated with a drug called paclitaxel.

These devices include stents and balloons used for arterial revascularisation in the lower limbs. Paclitaxel is added in order to limit the growth of scar tissue and reduce further blockages in the arteries.

The safety warning was released in January by the US Food and Drug Administration and was based on a meta-analysis of 28 trials involving 4,663 patients, indicating a doubling in mortality rate for people fitted with these devices.

Now, Dr Eva Freisinger, of the University Hospital Munster, Germany, and colleagues are publishing their study of 64,771 people which found no increase in deaths compared with patients using bare-metal stents or balloons not coated with paclitaxel.

Patients in the study underwent 107,112 procedures to unblock arteries with paclitaxel-coated devices, between 2007 and 2015. Details appear in the European Heart Journal today (9 October).

“Our findings show that paclitaxel-based devices are safe and are not associated with an increase of death,” said Dr Freisinger. “To our knowledge, this is the largest real-life group of patients that has been evaluated with long-term follow-up from the time that paclitaxel-coated devices were first introduced.

“Our work provides a solid base of evidence that will be difficult to rebut. We expect the FDA and other regulatory authorities will very likely amend their statements on safety concerns on paclitaxel-based devices.”

She added: “Our study illustrates the value of research using data from health services to rapidly assess safety concerns in real-life groups of patients.”

Freisinger, E. et al. Mortality of paclitaxel-based devices: a real-world safety analysis. European Heart Journal 9 October 2019 doi: 10.1093/eurheartj/ehz698

https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehz698

Tags: Europe | Heart Health | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES